← Back to Patent Explorer
US4059694A Expired / Lapsed US ⏱️ 0.0 years remaining

Cardiotonic agent

Assignee: University of Hawaiʻi at Mānoa
•
Filing: 1976-08-02
•
Granted: 1977-11-22
•
Expires: 1996-08-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A peptide designated anthopleurin-A, hereinafter also referred to as AP-A, obtained from the sea anemone Anthopleura xanthogrammica is found to possess cardiotonic activity.

Inventors

  • 👤 Ted R. Norton
  • 👤 Shoji Shibata
  • 👤 Midori Kashiwagi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 07:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/43504; C07K14/43595; A; A61; A61P; A61P9/00; A61P9/04

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 12 words
A peptide according to claim 1 having the amino acid sequence: Gly-Val-Ser-Cys-Leu-Cys-Asp-Ser-Asp-Gly-Pro-Ser-Val-Arg-Gly-Asn-Thr-Leu-Ser-Gly-Thr-Leu-Trp-Leu-Tyr-Pro-Ser-Gly-Cys-Pro-Ser-Gly-Trp-His-Asn-Cys-Lys-Ala-His-Gly-Pro-Thr-Ile-Gly-Trp-Cy-Cys-Lys-Gln.
Claim 2
Dependent Claim 109 words
A process for the preparation of anthopleurin-A from sea anemone, wherein the concentration of the intial alcohol extract is carried out at below 40° C and all other steps are carried at room temperature or below which comprises: a. extracting the sea anemones with water or with an aqueous-alcoholic mixture; b. subjecting the extract to gel filtration chromatography on a column of cross-linked dextran eluted with NH 4 HCO 3 solution and collecting and lylophilizing the active fraction; c. subjecting the active fraction to chromatography on a column of cation exchange resin eluted with a phosphate buffer with a gradient of NaCl and collecting and lyophilizing the active fraction.
Claim 3
Dependent Claim 109 words
A process for the preparation of anthopleurin-A from sea anemone, wherein the concentration of the intial alcohol extract is carried out at below 40° C and all other steps are carried at room temperature or below which comprises: a. extracting the sea anemones with water or with an aqueous-alcoholic mixture; b. subjecting the extract to gel filtration chromatography on a column of cross-linked dextran eluted with NH 4 HCO 3 solution and collecting and lylophilizing the active fraction; c. subjecting the active fraction to chromatography on a column of cation exchange resin eluted with a phosphate buffer with a gradient of NaCl and collecting and lyophilizing the active fraction.
Claim 4
Dependent Claim 64 words
A process according to claim 2, which comprises: d. subjecting the active fraction obtained in c) to chromatography on a column of cross-linked dextran eluted with a NaCl solution and collecting and lyophilizing the active fraction; e. desalting the active fraction obtained in d) by chromatography on a column of cross-linked dextran eluted with dilute acetic acid and collecting and lyophilizing the active fraction.
Claim 5
Dependent Claim 13 words
The process according to claim 2, wherein the sea anemone is Anthopleura xanthogrammica.
Claim 6
Dependent Claim 94 words
The process according to claim 4 which comprises the following steps: a. extracting the sea anemone, Anthopleura xanthogrammica, with 30% aqueous ethanol; b. subjecting the extract to gel filtration chromatography on a column of cross-linked carboxymethyl dextran having an exclusion limit of 30,000 eluted with 0.1M NH 4 HCO 3 solution and collecting and lyophilizing the active fraction; c. subjecting the active fraction to chromatography on a column of weakly acidic cation exchange resin eluted with 0.03M phosphate buffer at pH 7.5 and a gradient of 0.5N NaCl, collecting and lyophilizing the active fraction.
Claim 7
Dependent Claim 98 words
The process according to claim 5 which comprises: d. subjecting the active fraction obtained in c) to chromatography on a column of cross-linked dextran with an exclusion limit of 30,000 eluted with 0.017 M acetic acid which is 0.03M is NaCl and collecting and lyophilizing the active fraction; e. desalting the active fraction obtained in d) by placing a solution of said active fraction on a column of cross-linked dextran with an exclusion limit of 700 followed by a solution of 20% sodium chloride solution and eluting with 0.017M acetic acid and collecting and lyophilizing the active fraction.
Claim 8
Dependent Claim 19 words
The pharmaceutcial preparation which comprises the peptide of claim 1 in admixture or conjunction with a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim 18 words
The method of treating heart failure by administering a cardio effective amount of the peptide of claim 1.

References Cited (Backward Citations)

GB1411184A Cited
US3951939A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-11-21 1981-05-23 1981-11-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-11-21 1985-05-23 1985-11-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-11-21 1989-05-23 1989-11-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag